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Purpose: Although standard heparin has been demonstrated to reduce endothelial cell 
dysfimction in acute ischemia-reperfusion injury, its mechanism of action remains 
unknown. We hypothesized that heparin's alutary endothelial effects are independent of 
its conventional nticoagulant activity and are not caused by nonspecific polyanion effects. 
Methods: Isolated rat hindlimbs were perfused at constant pressure with an albumin- 
enriched crystalloid buffer. After 60 minutes of normothermic ischemia, endothelial 
function was assessed by measurement of endothelial-dependent vasodilation by log 
increment infusion of acetylcholine. Endothelial-independent vasodilation was measured 
by exposure to nitroprusside. Some groups were pretreated with heparinoids possessing 
minimal or intermediate anticoagulant activity. 
Results: Treatment with heparinoids with low anticoagulant activity significantly increased 
endothelial-dependent vasodilation when compared with the nontreated ischemic group 
and were statistically indistinguishable from the nonischemic ontrol. Treatment with 
dextran sulfate, a randomly sulfated polymer with size and charge characteristics similar 
to heparin, did not change postischemic vasodilation. Endothelial-independent vasodi- 
lation was largely unaffected by ischemia-reperfusion r drug treatment. 
Conclusions: A heparinoid with negligible antithrombin-binding activity (Astenose) 
attenuated postischemic endothelial dysfunction, suggesting that its mechanism of action 
was independent of anticoagulant activity. Failure of dextran sulfate to be protective 
implied that the effect was not caused by nonspecific polyanion action. (J VAsc SURG 
1995;21:477-83.) 
In acute ischemia, pharmaceutical heparin is 
frequently used to retard thrombus formation or 
propagation. Reduced endothelial and end-organ 
injury after heparin administration in experimental 
models of myocardial, 1 cerebral, 2 and extremity 3,4 
ischemia-reperfusion injury appears to support this 
use. However, the mechanism of heparin's protective 
effect is unknown. Although heparin is used during 
these acute ischemic events for its antithrombotic 
effect, some of its salutary actions may be unrelated 
to anticoagulant activity. 
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We have previously demonstrated that standard 
porcine mucosal heparin attenuated postischemic 
endothelial cell dysfunction as measured by release of 
nitric oxide. 5 The ability of heparin to preserve 
postischemic nitric oxide release was dose dependent, 
providing a maximal protective ffect at 4 Ixg/ml (0.5 
U/ml). s These protective endothelial actions of 
heparin were believed to be independent of its 
anticoagulant activity because the rat hindlimb was 
perfused with a crystalloid-based buffer devoid of 
circulating plasma proteins or cells. Heparin can be 
chemically modified to have negligible anticoagulant 
activity while retaining many of its other biologic 
activities. We hypothesized that such a nonantico- 
agulant heparin might provide similar postischemic 
endothelial protective ffects. 
An isolated rat hindlimb model of acute ischemia 
and reperfusion was used to study the effects of 
several heparin preparations on postischemic endo- 
thelial cell function. In addition to a heparinoid with 
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negligible antithrombin-binding activity (Astenose), 
a low-molecular-weight heparinoid (ORG-10172) 
and standard heparin were separately evaluated for 
their ability to preserve postischemic endothelial cell 
function. Dextran sulfate was also studied to evaluate 
the effect of a randomly sulfated polymer with size 
and charge characteristics similar to heparin. Endo- 
thelial cell function was assessed by measurement of 
nitric oxide release from the intact vasculature of the 
postischemic rat hindlimb. 
MATERIAL AND METHODS 
Animal care complied with the "Principles of 
Laboratory Animal Care" (formulated by the Na- 
tional Society for Medical Research) and the Guide for 
the Care and Use ofLaboratory Animals (NIH Publica- 
tion No. 86-23, revised 1985). All studies were ap- 
proved by the Animal Care and Use Committee of 
Virginia Commonwealth University/Medical Col- 
lege of Virginia. 
Model. A previously described isolated rat hind- 
limb model peffused with modified Krebs-Henseleit 
buffer was used in these studies, 6'7 Briefly, the perfu- 
sion apparatus was gravity fed and delivered a con- 
stant perfusion pressure of 70 mm Hg. The perfusate 
chambers and all tubing delivering perfusate to the 
limb were waterjacketed to maintain aconstant tem- 
perature of 37 ° C. By halting arterial perfusate flow, 
the limb could be subjected to complete ischemia. 
Male Sprague-Dawley rats weighing 325 to 400 
grams were anesthetized with pentobarbital 50 
mg/kg intraperitoneally, and the hindlimb was 
skinned. The femoral artery and vein were isolated 
immediately distal to the inguinal igament and se- 
quentially cannulated with 24-gauge and 20-gauge 
Teflon catheters, respectively (Critikon, Tampa, 
Fla.). The femoral artery was flushed with standard 
pharmaceutical-grade heparin (Lyphomed, Rose- 
mont, Ill.) 500 U in 0.5 ml normal saline solution 
before venous cannularion. The limb was then ampu- 
tated, and perfusion was immediately begun with a 
crystalloid-based buffer (see below). Saline solution- 
soaked gauzes were placed around the limb to pre- 
vent desiccation during the study. Limb temperature 
was maintained at 37 ° __. 0.2 ° C throughout the ex- 
periment, including the ischemic interval. Venous 
flow from the hindlimb was measured by timed col- 
lection over a 30-second interval and expressed per 
gram dry limb weight (ml/min/gm dry limb wt). 
Venous effluent was not recirculated. 
Perfusate and reagents. The perfiasate was a 
modified Krebs-Henseleit buffer s'r of the following 
composition (mmol/L): NaCI 118.4, KCI 4.7, CaC12 
2.5, KH2PO 4 1.2, MgSO4-7H20 1.2, NaHCO s 
34.9, glucose 10.0 plus 4 gm/dl of serum bovine 
albumin (Sigma Chemical Co., St. Louis, Mo.). The 
peffusate was prepared aily and filtered through a 
1.2 ~m nylon filter (MSI, Westboro, Mass.) before 
use. The buffer was constantly bubbled with 95% 
O2/5% CO 2 during the studies and was not recircu- 
lated. 
Phenylephrine HCI (1.0 to 2.5 t~mol/L; Win- 
throp-Breon, New York, N.Y.) was added irectly to 
the perfusate to preconstrict the limb to a standard 
total vascular esistance. 7 Acetylcholine CI (0.001, 
0.01, 0.1, 1.0 i~g/min, Sigma) and sodium nitro- 
prusside (0.5, 5.0, 50 i~g/min, Elkins-Sirm, Cherry 
Hill, N.J.) were suspended in normal saline solution 
and delivered into the arterial perfusate line with an 
infusion pump (Harvard Model 901; Harvard Ap- 
paratus Co., Inc., South Natick, Mass.). Limb flow 
rates became steady after 10 minutes of perfusion 
with phenylephrine and 1 to 1.5 minutes with 
acetylcholine and nitroprusside. 7 Indomethacin (2.8 
I~mol/L, Sigma Chemical Co.) was diluted in 0.1 
mol/L Na2CO 3 and added irectly to the perfusate to 
inhibit prostanoid production. 7's 
Three heparin preparations were individually 
added to both the preischemic and postischemic 
perfusate at a concentration of 4 I~g/ml (0.5 USP 
units/ml). Previous dose response studies with stan- 
dard heparin showed this concentration to have maxi- 
mal endothelial protective ffects. 5 This pharmaco- 
logic dose correlates with the average plasma heparin 
level in a patient reated with therapeutic anticoagu- 
lafion (activated partial thromboplasrin time [aPTT] 
2 x control).9 The following heparins were used: (1) 
a standard pharmaceutical-grade porcine intestinal 
mucosal heparin (lot no. 301182, Lyphomed); (2) a 
heparin whose antithrombin-binding activity had 
been chemically destroyed by periodate oxidation of 
standard porcine heparin (Astenose; Glycomed, Inc., 
Alameda, Calif.); (3) a low-molecular-weight hep- 
arinoid (ORG-10172 [Lomoparan], batch BT, Or- 
ganon, Inc., West Orange, N.J.). Dextran sulfate (lot 
116F-0296, Sigma) was also used in separate xperi- 
ments at a concentration f 4 t~g/ml. 
Potency of heparins. In vitro anti-Xa activity 
was determined by use of a modification of the 
method of Teien. 1° For each heparin an aPTT 
dose-response curve was developed with use of 
semiautomated methods and reagents from Organon 
(Durham, N.C.). The relative concentration required 
to prolong the aPTT to twice the control value was 
expressed as a percentage of the potency of the 
standard porcine mucosal heparin. 
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Experimental protocol. All limbs were initially 
perfused for a 20-minute stabilization period. Con- 
trol (nonischemic) limbs were then perfused for 60 
minutes without ischemia. Native venous flow was 
measured after the 20-minute stabilization period, 
and phenylephrine was then added to the perfusate to 
preconstrict the vasculature. After 10 minutes of 
perfusion with phenylephrine, the preconstricted 
flow rate was recorded, which was used as the 
baseline for subsequent measurements. Endothelial- 
dependent vasoreactivity (nitric oxide release) was 
then examined by measuring the change in flow in 
response to log increments of acetylcholine infused 
into the arterial perfusate line. 7 Flow measurements 
were taken 2 minutes after the initiation of each 
infusion. Endothelial-independent vasoreactivity was 
similarly assessed with nitroprusside after flow re- 
turned to its preconstricted baseline. Nitroprusside 
directly relaxes vascular smooth muscle. 
Postischemic limbs underwent an equivalent pe- 
riod of 20-minute stabilization perfusion and were 
then rendered totally ischemic for 60 minutes at 
37 ° -+ 0.2 ° C. The limbs were then reperfused with 
the buffer containing phenylephrine. After 10 min- 
utes, the preconstricted baseline was recorded, and 
vasoreactivity to acetylcholine and nitroprusside were 
tested as performed in the control imbs. Both con- 
trol and postischemic groups underwent identical 
amounts of perfusion (30 minutes) before adminis- 
tration of the agonists. 
Experimental groups. Six groups of limbs were 
studied. The control (nonischemic) group (n = 7) 
underwent no ischemia. Postischemic limbs were 
either untreated (n = 12) or pretreated with stan- 
dard heparin (n = 6), Astenose (n = 6), the low- 
molecular-weight heparin fraction ORG-10172 
(n = 5), or dextran sulfate (n = 7). These drugs 
were added to both the preischemic and postischemic 
perfusate. We have previously demonstrated that 
heparin had no effect on vasoreactivity of control 
(nonischemic) limb vasculature, s 
Data analysis and statistics. Total vascular 
resistance (TVR) was calculated by dividing the 
perfusion pressure (70 mm Hg) by the flow rate and 
expressed as mm Hg/ml/min/gm dry limb wt. 7 The 
effect of agonists on TVR was expressed as a percent 
change from the phenylephrine-preconstricted base-
line. 7,11 This baseline was measured before each dose 
response curve. 
Comparisons between the six experimental 
groups were made by one-way analysis of variance 
with Tuke~s studentized range test for comparison 
of variance between any two groups (SAS, Cary, 
N.C.). Groups were considered significantly different 
i fp < 0.05. All data are presented as mean +__ SE. 
RESULTS 
Baseline parameters. The native and precon- 
stricted TVR for the six experimental groups are 
presented in Table I. There were no significant 
differences between the native TVRs in the control 
(no ischemia) or nontreated ischemia group when 
compared with any of the treated ischemia groups. 
The native TVR of the ORG-10172 group was 
higher than that of the heparin group. Preconstricted 
TVRs, however, were not significantly different 
among the six experimental groups. 
Endothelial-dependent vasodilation. Infusion 
of log increments of acetylcholine caused graded 
reductions in limb TVR in the control (nonischemic) 
group (Fig. 1). Sixty minutes of normothermic 
ischemia nd 10 minutes of reperfusion (postisch- 
emic group) significantly impaired acetylcholine- 
induced vasodilation as reflected by a reduction in the 
percent change in TVR. In fact, during 0.01 wg/min 
acetylcholine infusion a paradoxic vasoconstriction 
was observed in this group. Groups pretreated with 
Astenose, ORG-10172, or standard heparin had a 
significant increase in postischemic endothelial- 
dependent vasodilation when compared with the 
untreated postischemic group (p < 0.05), and no 
paradoxic vasoconstriction occurred. These three 
groups were not significantly different from one 
another. Pretreatment with dextran sulfate did not 
significantly preserve postischemic vasodilation to 
acetylcholine. 
Endothelial-independent vasodilation. Infu- 
sion of log increments ofnitroprusside caused graded 
reductions inlimb TVR in the control group (Fig. 2). 
This endothelial-independent vasodilation was not 
significantly changed from control in the untreated 
postischemic, Astenose, ORG-10172, or standard 
heparin group. Vasodilation of the dextran sulfate 
group was not significantly different from any other 
postischemic group, but when compared with the 
control group, there was an isolated reduction of 
TVR, which was limited to the lowest dilution of 
nitroprusside (0.5 ~g/min). The dextran sulfate 
group was not significantly different from control 
when subjected to 5 or 50 wg/min of nitroprusside, 
however. 
DISCUSSION 
Ischemia-reperfusion-induced en othelial cell 
dysfunction was significantly reduced after pretreat- 
ment with Astenose, a heparin with negligible 
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Fig. 1. Endothelial-dependent vasodilation toacetylcholine as reflected by percent change in 
TVR. Two control groups underwent no ischemia s (n = 7) or 60 minutes of ischemia s 
(n = 12). Four groups underwent 60 minutes of ischemia fter pretreatment with Astenose 
(n = 6), ORG-10172 (n = 5), standard heparin s (n = 6), or dextran sulfate (n = 7). Limbs 
treated with dextran sulfate were not significantly different from ischemia control group. 
Table I. TVR 
Ischemia 
No ischemia No drug Heparin Astenose ORG- IO172 Dextran sulfate 
(n=7) (n=12) (n=6) (n=6) (n=5) (n=7) 
Native TVR 43.7 ± 3.7 39.1 + 3.6 35.9 -+ 1.9 46.9 + 2.2 50.0 + 2.4* 48.0 -+ 1.8 
Preconstricted TVR 95.5 ± 7.1 91.2 -+ 6.3 98.1 + 4.8 104.5 _+ 6.4 112.0 + 7.6 106.2 + 3.1 
*p < 0.05 versus native TVR in heparin group. Otherwise, p = NS between the six groups' native or preconstricted TVR. 
TVR is expressed in mm Hg/ml/min/gm dry limb weight. 
conventional nticoagulant activity. These protective 
effects, including elimination of the paradoxical 
vasoconstriction bserved, were statistically indistin- 
guishable from that conferred by standard heparin. 
Astenose is produced by a proprietary process of 
periodate oxidation of standard porcine mucosal 
heparin. This produces a heparinoid with minimal 
antithrombin binding activity, as reflected in the 
low aPTT activity (Table II). In contrast, standard 
heparin has approximately 180 anti-Xa units of 
anticoagulant activity and binds antithrombin III 
avidly. We had previously hypothesized that hep- 
arin's salutary effects on postischemic endothelial cell 
function may be independent of its conventional 
anticoagulant activity, s The demonstration f com- 
parable salutary effects of a heparin with negligible 
anticoagulant activity provide strong confirmatory 
evidence for this hypothesis. 
ORG-10172, a heparinoid preparation with in- 
termediate conventional nticoagulant effects, was 
also examined for its potential endothelial pro- 
tective ffects. ORG-10172 is composed of a mixture 
of glycosaminoglycans, including heparan sulfate 
( -80%),  dermatan sulfate (8% to 16%), and chon- 
droitin sulfate (< 9%). This compound has a much 
lower affinity for antithrombin III when compared 
with standard heparin but does have significant 
anti-Xa activity (Table II). Pretreatment with ORG- 
10172 also significantly attenuated postischemic 
endothelial cell damage. Thus two glycosaminogly- 
can preparations with different anticoagulant poten- 
cies produced similar effects on postischemic endo- 
thelial cell function. These data add further credence 
to the notion that the endothelial protective effects of 
various heparin preparations were not a factor of their 
anticoagulant activity. 
Paradoxic vasoconstriction f vessels exposed to a 
compound that usually causes dilation is a well- 
described phenomenon. 12 Typically this deleterious 
event occurs in blood vessels that have been injured. 
Indeed, in the untreated control group undergoing 
ischemia nd reperfusion, paradoxic vasoconstriction 
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Fig. 2. Endothelial-independent vasodilation to nitroprusside asreflected by percent change in 
TVR. Two control groups underwent no ischemia ~(n = 7) or 60 minutes of ischemia s 
(n = 12). Four groups underwent 60 minutes of ischemia after pretreatment with Astenose 
(n = 6), ORG-10172 (n = 5), standard heparin 5(n = 6), or dextran sulfate (n = 7). There 
were no significant differences between any group at any nitroprusside dose with exception of 
ischemia + dextran sulfate group versus nonischemic ontrol at 0.5 ~g/min nitroprusside 
(p < 0.05). 
Table II. Potency of heparins 
Heparin type Anti-Xa activity (units~rag) aPTT activity (%) Average tool. wt. (Daltons) 
Porcine mucosal heparin 180 100 15,000 
Astenose < 5 10 11,000 
ORG-10172 (Lomoparan) 15 10 6,000 
Dextran sulfate < 5 < 5 8,000 
aPTT, Activated partial thromboplastin time; mol. wt., molecular weight. 
was observed. This phenomenon was not seen in the 
nonischemic control group, suggesting that the 
paradoxical vasoconstriction was a consequence of 
the ischemia and not the use of acetylcholine per se. 
All heparinoids were equally effective in obviating 
this deleterious vasoconstriction. 
The protective effects of heparin and related 
glycosaminoglycans on endothelial function have 
been studied in several divergent models of experi- 
mental cellular injury. Heibert et al. 13 exposed 
endothelial cell cultures to xanthine and xanthine 
oxidase with presumptive liberation of damaging 
oxygen free radicals. Pretreatment with heparin in- 
creased cell viability and reduced lactate dehydroge- 
nase (LDH) release when compared with nontreated 
control subjects. Pretreatment with heparan sulfate, a 
heparin with reduced anticoagulant activity, also 
produced an increase in cell viability but no change in 
LDH release.~3 After balloon cathete r injury of rabbit 
aortas, Light et al. 14 found that heparin treatment 
normalized the structure of subsequently formed 
neoendothelium and also increased its endothelium- 
derived relaxing factor (EDRF) release when com- 
pared with untreated controls. Treatment with low- 
molecular-weight eparin had no beneficial effects, 
however. Hemorrhagic shock-induced cardiac, he- 
patic, and renal dysfunction has been attenuated after 
treatment with both standard is and nonanticoagu- 
lant heparin. 16 Preliminary work also suggested that 
systemic treatment with heparan sulfate attenuated 
gut dysfunction caused by hemorrhagic shock. 17 
Thus heparin and related glycosaminoglycans appear 
to confer protective effects under a variety of 
experimental conditions. 
Heparins are strongly polyanionic compounds 
and as such could confer beneficial membrane- 
stabilizing effects to injured endothelium. ~8 To in- 
vestigate the possibility that the salutary effects of 
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heparin in this study might be due to nonspecific 
polyanionic effects, a separate xperimental group 
was treated with dextran sulfate. This randomly 
sulfated polymer has size and charge characteristics 
similar to that of heparin (Table II). We found that 
dextran sulfate did not attenuate postischemic endo- 
thelial damage in this model, suggesting that the 
beneficial effects of heparin were not a nonspecific 
polyanion effect. However, others have arrived at the 
opposite conclusion. In endothelial cell cultures 
exposed to xanthine and xanthine oxidase, Heibert et 
al.ls found that pretreatment with dextran sulfate 
(mol wt 8000, 5 ~g/ml) did have salutary effects, 
producing increased cell viability and reduced LDH 
release. 13 The large differences between our ex vivo 
model and this in vitro study make comparisons of 
these data problematic. Further study with this 
compound may be warranted. 
Endothelial-independent vasodilation of the 
postischemic hindlimbs was largely unaffected by 
treatment with the various heparin preparations. 
Limbs treated with dextran sulfate had an isolated 
reduction in vasodilation when compared with the 
nonischemic control at the lowest dilution of nitro- 
prusside. However, none of the drug treatment 
groups (heparin, Astenose, ORG-10172, dextran 
sulfate) were significantly different from one another. 
Thus the maintenance of postischemic vasoreactivity 
of the hindlimbs after treatment with Astenose, 
ORG-10172, or standard heparin did not appear to 
be caused by direct effects on the vascular smooth 
muscle. 
Measurement of endothelial dysfunction. En- 
dothelial cell dysfunction was assessed by measure- 
ment of EDRF release from the intact vasculature of 
the rat hindlimb. Previous work by us ~ and others 19 
using competitive inhibitors of nitric oxide release 
such as NC-monomethyl-L-arginine i  intact hind- 
limb models have confirmed that nitric oxide is the 
principle EDRF in these preparations. The ability of 
endothelium to release nitric oxide is a sensitive 
indicator of its functional status; reductions in nitric 
oxide release can actually precede nd-organ i jury. 2° 
Thus measurement of EDRF (nitric oxide) release is 
a valid parameter in the assessment of endothelial 
damage from ischemia-reperfusion injury. 
Limitations of study. Drug treatment was 
initiated before the onset of ischemia. It is not yet 
known whether delayed administration of these 
heparinoids would be as beneficial. In an in vivo 
canine hindlimb model, Ricci et al.21 have shown that 
standard heparin administered 30 minutes before 
reperfusion after 4 hours of ischemia reduced subse- 
quent skeletal muscle necrosis. In this study only a 
single parameter of endothelial cell injury was exam- 
ined. However, we have subsequently demonstrated 
significant reductions in vascular permeability with 
heparin treatment in this model (unpublished obser- 
vations). Others have also demonstrated anattenua- 
tion of the rise in postischemic permeability, as well 
as reductions in skeletal muscle necrosis with stan- 
dard heparin treatment.3 Finally, because of the small 
sample sizes, the possibility of a type II error could 
not be eliminated in the dextran sulfate groups. 
Heparinoid pretreatment provided significant 
protection from endothelial damage caused by isch- 
emia and reperfusion. The inability of dextran sulfate 
to reduce ndothelial dysfunction suggested that the 
beneficial effects were not a nonspecific polyanion 
effect. The protective ffect of these heparinoids 
appeared to be unrelated to anticoagulant activity 
because they possessed only minimal (Astenose) or 
intermediate (ORG-10172) conventional nticoagu- 
lant activity. 
Endothelial dysfianction is a common feature of 
organ dysfunction i  septic and hemorrhagic shock, 
myocardial nd extremity ischemia, and transplanted 
organs. Accordingly, further study of these hep- 
arinoids are warranted for potential use as endothelial 
protective agents. 
We thank Glycomed, Inc., for providing Astenose and 
Organon, Inc., for supplying ORG-10172 for this study. 
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